Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia

Journal of Immunology

Volumn 192, Issue 10, 2014, Pages 4592-4600

  Cooley, Sarah ^a   Weisdorf, Daniel J ^a   Guethlein, Lisbeth A ^b   Klein, John P ^c   Wang, Tao ^c   Marsh, Steven G E ^d   Spellman, Stephen ^e   Haagenson, Michael D ^e   Saeturn, Koy ^f   Ladner, Martha ^f   Trachtenberg, Elizabeth ^f   Parham, Peter ^b   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^e CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^f CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA C ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOTYPE; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DONOR; GENE; GENE INTERACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA C GENE; HLA C1 GENE; HOMOZYGOSITY; HUMAN; KIR B GENE; LEUKEMIA FREE SURVIVAL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROTEIN MOTIF; RECIPIENT; SURVIVAL; TREATMENT RELATED MORTALITY;

ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-C ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; RECEPTORS, KIR; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNRELATED DONORS;

EID: 84901290331     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302517     Document Type: Article

References (37)

1. Shilling, H. G., N. Young, L. A. Guethlein, N. W. Cheng, C. M. Gardiner, D. Tyan, and P. Parham. 2002. Genetic control of human NK cell repertoire. J. Immunol. 169: 239-247.
2. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
3. Ruggeri, L., M. Capanni, M. Casucci, I. Volpi, A. Tosti, K. Perruccio, E. Urbani, R. S. Negrin, M. F. Martelli, and A. Velardi. 1999. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
4. Ruggeri, L., A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, et al. 2007. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110: 433-440.
5. Ruggeri, L., A. Mancusi, E. Burchielli, F. Aversa, M. F. Martelli, and A. Velardi. 2007. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr. Opin. Oncol. 19: 142-147.
6. Hsu, K. C., T. Gooley, M. Malkki, C. Pinto-Agnello, B. Dupont, J. D. Bignon, M. Bornhäuser, F. Christiansen, A. Gratwohl, Y. Morishima, et al; International Histocompatibility Working Group. 2006. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol. Blood Marrow Transplant. 12: 828-836.
7. Malmberg, K. J., M. Schaffer, O. Ringdén, M. Remberger, and H. G. Ljunggren. 2005. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol. Immunol. 42: 531-534.
8. Giebel, S., F. Locatelli, T. Lamparelli, A. Velardi, S. Davies, G. Frumento, R. Maccario, F. Bonetti, J. Wojnar, M. Martinetti, et al. 2003. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102: 814-819.
9. Farag, S. S., A. Bacigalupo, M. Eapen, C. Hurley, B. Dupont, M. A. Caligiuri, C. Boudreau, G. Nelson, M. Oudshoorn, J. van Rood, et al; KIR Study Group, Center for International Blood and Marrow Transplantation Research. 2006. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol. Blood Marrow Transplant. 12: 876-884.
10. Leung, W. 2011. Use of NK cell activity in cure by transplant. Br. J. Haematol. 155: 14-29.
11. Cook, M. A., D. W. Milligan, C. D. Fegan, P. J. Darbyshire, P. Mahendra, C. F. Craddock, P. A. Moss, and D. C. Briggs. 2004. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103: 1521-1526.
12. Giebel, S., F. Locatelli, J. Wojnar, A. Velardi, T. Mina, G. Giorgiani, M. Krawczyk-Kulis, M. Markiewicz, I. Wylezol, and J. Holowiecki. 2005. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br. J. Haematol. 131: 483-486.
13. Cooley, S., E. Trachtenberg, T. L. Bergemann, K. Saeteurn, J. Klein, C. T. Le, S. G. Marsh, L. A. Guethlein, P. Parham, J. S. Miller, and D. J. Weisdorf. 2009. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113: 726-732.
14. Cooley, S., D. J. Weisdorf, L. A. Guethlein, J. P. Klein, T. Wang, C. T. Le, S. G. Marsh, D. Geraghty, S. Spellman, M. D. Haagenson, et al. 2010. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116: 2411-2419.
15. Houtchens, K. A., R. J. Nichols, M. B. Ladner, H. E. Boal, C. Sollars, D. E. Geraghty, L. M. Davis, P. Parham, and E. A. Trachtenberg. 2007. Highthroughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles. Immunogenetics 59: 525-537.
16. Hollenbach, J. A., M. B. Ladner, K. Saeteurn, K. D. Taylor, L. Mei, T. Haritunians, D. P. McGovern, H. A. Erlich, J. I. Rotter, and E. A. Trachtenberg. 2009. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics 61: 663-671.
17. Boyington, J. C., and P. D. Sun. 2002. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol. Immunol. 38: 1007-1021.
18. Valiante, N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7: 739-751.
19. Gumperz, J. E., V. Litwin, J. H. Phillips, L. L. Lanier, and P. Parham. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181: 1133-1144.
20. Gumperz, J. E., L. D. Barber, N. M. Valiante, L. Percival, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J. Immunol. 158: 5237-5241.
21. Thananchai, H., G. Gillespie, M. P. Martin, A. Bashirova, N. Yawata, M. Yawata, P. Easterbrook, D. W. McVicar, K. Maenaka, P. Parham, et al. 2007. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178: 33-37.
22. Hansasuta, P., T. Dong, H. Thananchai, M. Weekes, C. Willberg, H. Aldemir, S. Rowland-Jones, and V. M. Braud. 2004. Recognition of HLA-A3 and HLAA11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34: 1673-1679.
23. Pyo, C. W., L. A. Guethlein, Q. Vu, R. Wang, L. Abi-Rached, P. J. Norman, S. G. Marsh, J. S. Miller, P. Parham, and D. E. Geraghty. 2010. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS ONE 5: e15115.
24. Petersdorf, E. W. 2008. Optimal HLA matching in hematopoietic cell transplantation. Curr. Opin. Immunol. 20: 588-593.
25. Moesta, A. K., P. J. Norman, M. Yawata, N. Yawata, M. Gleimer, and P. Parham. 2008. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 180: 3969-3979.
26. Winter, C. C., J. E. Gumperz, P. Parham, E. O. Long, and N. Wagtmann. 1998. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161: 571-577.
27. Schölnberg, K., M. Sribar, J. Enczmann, J. C. Fischer, and M. Uhrberg. 2011. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 117: 98-107.
28. Bari, R., T. Bell, W. H. Leung, Q. P. Vong, W. K. Chan, N. Das Gupta, M. Holladay, B. Rooney, and W. Leung. 2009. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 114: 5182-5190.
29. Yawata, M., N. Yawata, M. Draghi, F. Partheniou, A. M. Little, and P. Parham. 2008. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112: 2369-2380.
30. Venstrom, J. M., G. Pittari, T. A. Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. M. Gallagher, M. Malkki, E. Petersdorf, B. Dupont, and K. C. Hsu. 2012. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367: 805-816.
31. Venstrom, J. M., T. A. Gooley, S. Spellman, J. Pring, M. Malkki, B. Dupont, E. Petersdorf, and K. C. Hsu. 2010. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 115: 3162-3165.
32. Fauriat, C., M. A. Ivarsson, H. G. Ljunggren, K. J. Malmberg, and J. Michaëlsson. 2010. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 115: 1166-1174.
33. Gourraud, P. A., A. Meenagh, A. Cambon-Thomsen, and D. Middleton. 2010. Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses. Immunogenetics 62: 729-740.
34. Frazier, W. R., N. Steiner, L. Hou, S. Dakshanamurthy, and C. K. Hurley. 2013. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J. Immunol. 190: 6198-6208.
35. Hilton, H. G., L. Vago, A. M. Older Aguilar, A. K. Moesta, T. Graef, L. Abi- Rached, P. J. Norman, L. A. Guethlein, K. Fleischhauer, and P. Parham. 2012. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J. Immunol. 189: 1418-1430.
36. Bjölrkströlm, N. K., P. Riese, F. Heuts, S. Andersson, C. Fauriat, M. A. Ivarsson, A. T. Bjölrklund, M. Flodströlm-Tullberg, J. Michaëlsson, M. E. Rottenberg, et al. 2010. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116: 3853-3864.
37. Andrews, D. M., A. A. Scalzo, W. M. Yokoyama, M. J. Smyth, and M. A. Degli- Esposti. 2003. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol. 4: 175-181.